ImmunoGen, Inc. Announces Genentech, Inc. Has Taken Fourth License To Use ImmunoGen's TAP Technology To Develop Novel Anticancer Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 13, 2005--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Genentech (NYSE: DNA) has licensed exclusive rights to use ImmunoGen's Tumor-Activated Prodrug (TAP) technology with therapeutic antibodies to an undisclosed target. This is the fourth such license to be taken by Genentech, which also has licensed exclusive rights to use ImmunoGen's TAP technology with therapeutic antibodies to two other undisclosed targets and to HER2.